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Abstract
Although aromatase inhibitors (AIs) are commonly used therapies for breast cancer, their use is 
limited because they produce arthralgia in a large number of patients. To determine whether AIs 
produce hypersensitivity in animal models of pain, we examined the effects of the AI, letrozole, on 
mechanical, thermal, and chemical sensitivity in rats. In ovariectomized (OVX) rats, administering 
a single dose of 1 or 5 mg/kg letrozole significantly reduced mechanical paw withdrawal 
thresholds, without altering thermal sensitivity. Repeated injection of 5 mg/kg letrozole in male 
rats produced mechanical, but not thermal, hypersensitivity that extinguished when drug dosing 
was stopped. A single dose of 5 mg/kg letrozole or daily dosing of letrozole or exemestane in male 
rats also augmented flinching behavior induced by intraplantar injection of 1000 nmol of 
adenosine 5′-triphosphate (ATP). To determine whether sensitization of sensory neurons 
contributed to AI-induced hypersensitivity, we evaluated the excitability of neurons isolated from 
dorsal root ganglia of male rats chronically treated with letrozole. Both small and medium-
diameter sensory neurons isolated from letrozole-treated rats were more excitable, as reflected by 
increased action potential firing in response to a ramp of depolarizing current, a lower resting 
membrane potential, and a lower rheobase. However, systemic letrozole treatment did not augment 
the stimulus-evoked release of the neuropeptide calcitonin gene-related peptide (CGRP) from 
spinal cord slices, suggesting that the enhanced nociceptive responses were not secondary to an 
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increase in peptide release from sensory endings in the spinal cord. These results provide the first 
evidence that AIs modulate the excitability of sensory neurons, which may be a primary 
mechanism for the effect of these drugs to augment pain behaviors in rats.
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electrophysiology; excitability; calcitonin gene-related peptide
Introduction
Aromatase inhibitors (AIs) are effective therapies for hormone sensitive breast cancer in 
postmenopausal women, presumably through their ability to inhibit the biosynthesis of 
estradiol and estrone (Dowsett et al., 1995; Geisler et al., 2002; Geisler et al., 1998). Studies 
indicate that up to 50% of breast cancer patients develop pain in joints and/or muscles within 
weeks to months of initiating AI therapy (Crew et al., 2007; Henry et al., 2007), and this 
results in approximately one-fourth of these patients discontinuing therapy (Henry et al., 
2012). Since there are no objective measures of pathophysiologic changes underlying AI-
associated pain, clinical description has mainly focused on subjective evaluation. Patient-
reported pain displays large inter-subject variability in the number of joints involved, as well 
as the intensity and quality of pain, which has been described by patients as “achy”, “stiff”, 
“tingling”, and “numbness” (Henry et al., 2007). Based on clinical evaluation, patients with 
AI-induced musculoskeletal pain are diagnosed with a range of conditions, including: 
tendonitis or tenosynovitis, osteoarthritis, and carpal tunnel syndrome, with multiple 
rheumatologic conditions diagnosed in a significant fraction of patients (Henry et al., 2007; 
Moxley, 2010), however, the high frequency of these conditions in post-menopausal women 
may confound these determinations (Lintermans et al., 2012; Moxley, 2010). Furthermore, it 
remains unclear whether these conditions contribute to AI-induced pain or are common 
comorbidities. Therapeutic approaches that effectively alleviate pain associated with 
inflammatory joint disorders, such as nonsteroidal anti-inflammatory drugs and 
acetaminophen, are largely ineffective in alleviating AI-induced musculoskeletal pain or 
improving patient persistence on AI therapy (Crew et al., 2007; Hashem et al., 2013; 
Martens et al., 2007; Morales et al., 2008). Additionally, factors associated with AI-induced 
arthralgia identified by clinical studies have been largely inconsistent and mechanisms 
mediating this side effect remain unknown (Henry et al., 2008).
Evidence suggests that AI-induced arthralgia is linked to the ability of AIs to reduce 
estrogen concentrations by blocking aromatase, the enzyme that catalyzes the conversion of 
testosterone to 17β-estradiol (Felson and Cummings, 2005; Henry et al., 2008). This notion 
is supported by clinical observations that musculoskeletal syndromes develop in patients 
during periods of low or declining systemic estrogens, such as during the transition into 
menopause (Berecki-Gisolf et al., 2009; Cecil and Archer, 1925; Meriggiola et al., 2012) or 
following discontinuation of estrogen replacement therapy (Brunner et al., 2010; Ockene et 
al., 2005). Studies using male and female rats show that estrogen administration produces 
antinociception in animal models of pain (Kuba et al., 2005; Liu and Gintzler, 2000; 
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Mannino et al., 2007; Tsao et al., 1999), suggesting that systemic estrogens may be negative 
regulators of pain.
Although the major source of endogenous estrogen in females is the ovaries, it is well 
established that males and females synthesize estrogens in other tissues including the central 
and peripheral nervous systems (Callard et al., 1978; Schaeffer et al., 2010). For instance, 
estradiol content in the rat central nervous system varies widely between brain regions. 
Furthermore, while region-specific content does not show a clear correlation with blood 
estradiol concentrations, regions with relatively high levels of aromatase activity correspond 
to high estradiol content (Konkle and McCarthy, 2011). The expression of enzymes 
necessary for estrogen synthesis (Schaeffer et al., 2010) and proteins mediating estrogen 
signaling cascades (Papka and Storey-Workley, 2002; Takanami et al., 2010; Taleghany et 
al., 1999) also are found in dorsal root ganglia (DRGs) and in primary sensory neurons. 
Consequently, aromatase inhibition in these tissues may be an important factor for AI-
induced toxicity, particularly when estrogen synthesis by the ovaries is diminished, such as 
during menopause or following oophorectomy.
Despite the clinical significance of AI-induced arthralgia, few studies have attempted to 
determine the effects of AIs in animal models of nociception (Evrard and Balthazart, 2004a, 
b; Fusi et al., 2014; Moradi-Azani et al., 2011). Consequently, we examined the effect of 
systemically administering letrozole to male and OVX female rats on nociceptive responses 
to mechanical and noxious thermal stimulation. Previous studies suggest that estradiol 
attenuates the excitatory effects of the nucleotide adenosine 5′-triphosphate (ATP) (Chaban 
et al., 2003; Cho and Chaban, 2012; Lu et al., 2013). Therefore, we additionally determined 
whether systemic administration of letrozole and exemestane (AIs with different 
mechanisms of action) could alter the nociceptive response to intraplantar injection of ATP. 
To directly assess the effect of systemic letrozole treatment on sensory neurons, we 
measured various parameters of excitability in sensory neurons acutely isolated from 
animals treated with the AI. Finally, we determined whether systemic administration of 
letrozole could alter the release of calcitonin gene-related peptide (CGRP) from sensory 
nerve endings in spinal cord slices. We chose to examine CGRP release, in part, because 
previous studies suggest that estrogens regulate CGRP expression in sensory neurons 
(Gangula et al., 2000). Our results demonstrate that rats administered aromatase inhibitors 
exhibit hypersensitivity to mechanical and chemical stimuli and enhanced excitability of 
sensory neurons. Preliminary findings have appeared in abstract form (Robarge et al., 2011).
Materials and Methods
Animals
Experiments were performed using adult male and female Sprague Dawley rats (150–200 
grams; Harlan Laboratories, Indianapolis, IN), housed two to three per cage under a 12-hour 
dark-light cycle. Ovariectomies were performed by the supplier during which rats were 
administered 41.7 mg ketamine (i.m.), 8.3 mg/kg xylazine (i.m.) and 3.0 mg/kg ketoprofen 
(s.q.). Wound clips used to close the surgical incisions were removed 10 days post-surgery, 
as recommended by the supplier. Male rats were housed for at least one week, while OVX 
rats were housed for at least two weeks, before beginning experiments. Food and water were 
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available ad libitum. All experiments were performed in accordance with the ethical 
guidelines for investigation of experimental pain in conscious animals and the guidelines of 
the Indiana University School of Medicine Institutional Animal Care and Use Committee 
(Zimmermann, 1983).
Chemicals
Letrozole and exemestane were obtained from United States Pharmacopeia (Rockville, MD). 
F-12 and DMEM/F-12 media, as well as heat-inactivated horse serum, glutamine, normocin, 
and penicillin-streptomycin were obtained from Life Technologies (Carlsbad, CA). Papain 
was obtained from Worthington (Lakewood, NJ). The rabbit anti-rat CGRP antiserum was a 
gift from Dr. Michael Iadorola (NIH) and its selectivity has been previously characterized 
(Vasko et al., 1994). All other chemicals and reagents were obtained from Sigma Chemical 
Company (St. Louis, MO).
Drug administration
In behavioral experiments, on the day of drug injection, letrozole and exemestane powders 
were dissolved in a 2.5 to 30 percent solution of hydroxypropyl-β-cyclodextrin (HPβCD) in 
sterile normal saline. AIs were administered by intraperitoneal (i.p.) injections (1 to 30 
mg/kg) using a 26G needle. In all experiments, animals in both experimental and control 
groups received equal amounts of HPβCD in equal injection volumes (5 mL/kg; 
approximately 1 mL). ATP was prepared in ice-cold sterile phosphate buffered saline 
(0.01M, pH 7.4) (PBS) and kept on ice until injection. Prior to injection, ATP and PBS 
vehicle solutions were drawn into a syringe and warmed to room temperature. Injections in 
the paw were administered intradermally in the mid-plantar footpad using a 31G needle (50 
µL injection volume).
Behavioral testing
Experiments were performed between 7 AM and 3 PM during the animals’ light cycle. After 
a minimum of one week in the animal care facility, animals were acclimated to the testing 
environment on multiple days for one week preceding any behavioral measurement or drug 
administration. Prior to each measurement session, animals were acclimated in the testing 
apparatus for approximately 30 minutes or until grooming or exploratory behavioral ceased. 
In all experiments, the observer was blinded to treatment and data analysis was completed at 
the conclusion of the experiment. In animals receiving chronic drug treatment, behavioral 
measures were assessed prior to the next daily drug administration.
For repeated measures experiments evaluating sensitivity to mechanical and thermal stimuli, 
baseline responses were obtained by exposing animals to stimuli two to three times on 
separate days prior to drug administration. The measurement immediately prior to the first 
drug injection, however, was used as the baseline response. In order to minimize the 
potential confounding effect of baseline response on drug-induced changes in these 
longitudinal experiments, both male and OVX rats were rank ordered with respect to 
baseline mechanical sensitivity, outliers (paw withdrawal threshold greater than 15 or less 
than 4 grams) were excluded, and the remaining animals were randomized into treatment 
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groups. Approximately 15% of animals evaluated at baseline were excluded from further 
testing.
The von Frey filament test was used to ascertain mechanical sensitivity. Rats were placed in 
an elevated cage with a wire mesh bottom that allowed for stimulation of hind paws. Paw 
withdrawal response to mechanical stimulation was evaluated with calibrated Semmes and 
Weinstein monofilaments, using a modification of the “up-down method” (0.4 – 26 grams, 
the lower and upper limit of the test; Stoelting, Wood Dale, IL) (Chaplan et al., 1994). 
Filaments were applied to the mid-plantar surface of each hind paw, with trials starting with 
the four gram filament. A trial consisted of three applications of a filament for 
approximately five seconds, with at least five seconds separating successive stimulation. A 
positive response was defined as an abrupt paw withdrawal when the stimulus was applied, 
or paw withdrawal immediately upon removal of the filament. The paw withdrawal 
threshold (PWT) in grams was the stimulus/filament evoking a paw withdrawal response in 
at least two of the three stimulations. PWT was measured for both hind paws and averaged 
to generate final withdrawal threshold at the specified time point.
The Hargreaves test was used to assess thermal sensitivity. Rats were placed in a ventilated 
acrylic cage atop a flat glass surface. Paw withdrawal latency (PWL) to noxious radiant heat 
was assessed using an infra-red (IR) heat source (Ugo Basile, Italy) applied to the mid-
plantar surface of each hind paw (Hargreaves et al., 1988). Upon initiating the thermal 
stimulus, an electronic timer was activated. A paw withdrawal (flinching or lifting the paw) 
was detected by a photocell, which switched off the IR source and timer, yielding the PWL. 
The heat source intensity was chosen to yield baseline paw withdrawal latencies of 10 
seconds in the rats. A cutoff of 30 seconds was used to avoid tissue damage to the paw. At 
least 30 seconds separated successive trials in the same animal. PWL from each hind paw 
was measured three times and all six measurements were averaged to generate the final 
latency in seconds at the specified time point.
Nociceptive behavior in response to ATP was made by observing unrestrained animals on a 
glass surface covered by an inverted and ventilated four liter plastic beaker. Mirrors were 
positioned below and behind the beaker for behavioral assessment, regardless of animal 
orientation. Once acclimated to the testing environment, animals were removed, lightly 
restrained, and administered an intradermal injection in the left hind paw. Animals were 
immediately returned to the testing apparatus and behavior was observed. As a measure of 
spontaneous nocifensive behavior, flinching or shaking of the injected paw or hindquarters 
was recorded (McGaraughty et al., 2003; Wheeler-Aceto and Cowan, 1991). Each observed 
behavior was recorded as one flinch and behavioral responses were tallied in one minute 
intervals for 10 minutes following the injection.
Isolation and cell culture of adult rat sensory neurons
Cultures of sensory neurons for electrophysiological studies were prepared using a protocol 
developed by Lindsay (Lindsay, 1988) and subsequently modified by Chi and Nicol (Chi 
and Nicol, 2007). Briefly, rats were sacrificed in a CO2 chamber and dorsal root ganglia 
(DRG) were dissected into an ice cold solution of Puck’s saline solution composed of (in 
mM): 171 NaCl, 6.7 KCl, 1.6 NaHPO4, 0.46 KH2PO4, and 6.1 D-glucose, pH 7.4. DRGs 
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were serially digested in F-12 medium containing 10 U/mL of papain (10 min at 37°C in 3% 
CO2) and 1 mg/mL collagenase IA / 2.5 mg/mL dispase (50 min at 37°C in 3% CO2). 
Following centrifugation (1000 g for 1 min) and resuspension in F-12 medium 
(supplemented with 10% heat-inactivated horse serum, 2 mM glutamine, 100 µg/mL 
normocin, 50 units/mL penicillin, 50 µg/mL streptomycin, 50 µM 5-fluoro-2’-deoxyuridine 
(FDU), and 150 µM uridine), the ganglia were mechanically dissociated into a single cell 
suspension using a fire-polished glass pipette. Cells were plated at an approximate density of 
7,500 cells per well of a 48-well plate containing plastic coverslips pre-coated with 0.1 
mg/mL of poly-D-lysine and 10 µg/mL of laminin. Cells were maintained in culture at 37°C 
and 3% CO2 for 2 to 6 hours before initiating patch clamp electrophysiology recordings.
Electrophysiological recording
Current clamp recording were performed using the whole-cell patch-clamp technique at 
room temperature (~23°C) (Hamill et al., 1981; Zhang et al., 2012). Briefly, plastic 
coverslips containing the sensory neurons were placed inside an open diamond bath chamber 
(Model RC-25, Warner Instruments, Hamden, CT, USA) containing a solution of normal 
Ringers composed of (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES and 10 
glucose (pH 7.4 with NaOH). Glass capillary tubes were used to pull recording pipettes with 
a Warner Instruments pipette puller (Model G85165T-4). The pipette resistance measured 2–
5 MΩ when filled with an intracellular solution composed of the following (in mM): 140 
KCl, 5 MgCl2, 4 ATP disodium salt, 0.3 GTP monosodium salt, 2.5 CaCl2, 5 EGTA (free 
Ca2+ concentration calculated at ~100 nM), and 10 HEPES (pH 7.3 with KOH). The final 
sodium concentration in the pipette solution was 8.3 mM. After achieving the whole-cell 
configuration, recordings were acquired with an Axopatch 200B amplifier (Molecular 
Devices, Sunnyvale, CA, USA). Traces from current clamp experiments were filtered at 5 
kHz and sampled at 2 kHz. The data were acquired and analyzed using either pCLAMP 8.0 
or pCLAMP 10.0.
Upon establishing the whole-cell configuration in either small-diameter (20 µm) or medium-
diameter (35 µm) sensory neurons, the cells were held at their resting membrane potentials, 
which ranged between −45 and −65 mV. Immediately thereafter, the cells were injected with 
a 500 picoampere (pA) ramp of depolarizing current over 1000 ms and the resulting action 
potentials (APs) were recorded. The same ramp of current was used in all cells independent 
of drug treatment to assess alterations in excitability caused by AI exposure. The AP traces 
were used to calculate all parameters of sensory neuronal excitability except for the rheobase 
and input resistance, which were determined by injecting a series of 200 millisecond (ms) 
current steps of variable incremental amplitudes until the firing of a single AP was observed. 
At the conclusion of each recording session, 300 nM of capsaicin was superfused into the 
recording chamber and AP firing measured to ascertain whether the neurons were capsaicin-
sensitive
Release of calcitonin gene-related peptide from spinal cord tissue
Spinal cord slices were prepared as previously described (Chen et al., 1996). After rats were 
sacrificed using CO2 asphyxiation and decapitation, a 1 cm segment of the lumbar 
enlargement was dissected, chopped transversely and parasagitally into 0.3 × 0.3 mm 
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sections, and placed into an individual cylindrical perfusion chamber. Slices were perfused 
at a flow rate of 0.5 ml/min with HEPES buffer (pH 7.4) supplemented with 200 µM 
ascorbic acid, 100 µM Phe-Ala, 20 µM bacitracin, and 10 µM phenylmethylsulfonyl fluoride 
(PMSF), aerated with 95% O2 – 5% CO2, and maintained at 37°C. After perfusing slices for 
20 minutes to equilibrate the tissue, perfusate was collected in 3 minute intervals throughout 
the experiment (1.5 ml/fraction) using an automatic fraction collector. Baseline release was 
established by perfusing tissue with HEPES for 18 minutes (6 fractions), with the last 3 
fractions used to determine basal or resting release. Subsequently, potassium-stimulated 
release was determined by perfusing tissue for an additional 9 minutes (3 fractions) with 
HEPES buffer containing 30 mM KCl (substituted for equimolar NaCl). Lastly, slices were 
perfused with HEPES buffer for 21 minutes (7 fractions) to re-establish basal release. 
Following tissue perfusion, spinal cord tissue was collected and homogenized in 2 ml of 0.1 
N HCl. Homogenates were centrifuged at 3,000 rpm for 20 minutes at 4°C. The supernatants 
were serially diluted with HEPES buffer and assayed for immunoreactive CGRP (iCGRP) 
along with perfusate fractions by radioimmunoassay as previously described (Chen et al., 
1996). The total iCGRP content in each tissue slice was calculated as content measured in 
all perfusate fractions plus tissue homogenate.
Statistical analysis
Unless otherwise specified, data are presented as mean ± standard error of the mean 
(S.E.M.) and statistical significance was set at p < 0.05. Effects of letrozole on PWT and 
PWL were analyzed using two-way analysis of variance with repeated measures (two-way 
RM-ANOVA), followed by post hoc two-sample t-tests. One-way RM-ANOVA was used to 
evaluate whether PWT and PWL changed over time during behavioral testing. Because PWT 
was measured using logarithmic intervals in pressure exerted by sequential filaments, log10-
transformed thresholds were used for data analysis. To compare treatment effects on PWT 
and PWL between studies, we normalized baseline responses by calculating percent change 
from baseline for each rat. In experiments evaluating overt nociceptive behavior, numbers of 
flinches observed in one-minute intervals were compared between treatment groups using 
the Mann-Whitney U test. Cumulative ATP-induced nociceptive behavior is reported as 
median (25th percentile, 75th percentile) and was compared between treatment groups using 
the Mann-Whitney U test. Boxplots depict overt nociceptive behavior as five-number 
summaries with horizontal lines representing (from top to bottom): 75th percentile + (1.5 × 
interquartile range) (upper whisker), 75th percentile, median, 25th percentile, 25th percentile 
- (1.5 × interquartile range) (lower whisker).
In order to determine the various parameters of excitability, the voltage was differentiated 
with respect to time (dV/dt) and the average of the voltage differential was calculated across 
the first 100 ms of the ramp stimulus in order to yield a baseline dV/dt. The firing threshold 
(FT) was the voltage at which the first AP was fired. This was taken as the point at which the 
dV/dt exceeded the baseline by greater than twenty-fold. The latency to fire was the time 
point in the ramp stimulus at which the FT was achieved. In order to determine input 
resistance, a negative current step of 200 ms duration was injected into the cell. The 
resulting peak potential achieved was subtracted from the resting membrane potential and 
the difference was divided by the value of the current step in order to yield the final input 
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resistance value. Statistical significance was determined by comparing groups to their 
respective vehicle controls using two-sample t-tests.
Peptide release from spinal cord tissue is expressed as the amount released per minute in 
each fraction, divided by the total iCGRP content for that spinal cord sample (percent of 
total content per minute). Treatment effects were evaluated by comparing peptide release 
during the three basal fractions to peptide release during the three stimulated fractions. The 
difference between iCGRP released during exposure to high potassium (stimulated) and 
iCGRP released during drug or vehicle exposure prior to high potassium stimulation (basal) 
is termed evoked release. Treatment effects on iCGRP content and release were evaluated 
using two-sample t-tests.
Results
A single dose of letrozole produces mechanical, but not thermal hypersensitivity in OVX 
rats
We examined whether AIs alter nociceptive responses in OVX rats by measuring changes in 
PWT and PWL following treatment with a single dose of 1 mg/kg or 5 mg/kg letrozole. We 
chose to use a single injection at these doses since they have previous been shown to inhibit 
aromatase in female rats (Schieweck et al., 1993) and pharmacokinetic studies suggest that 
the clearance of cyclodextrin-complexed letrozole is 5-fold slower in female rats when 
compared to males (Wempe et al., 2007). Administration of 1 mg/kg letrozole to OVX rats 
(n = 11) significantly reduced the response threshold to a mechanical stimulus compared to 
vehicle-treated controls (100 mg/kg HPβCD; n = 9) at 5, 10 and 30 days after drug 
administration (two-way RM-ANOVA with post-hoc t-tests, P < 0.05; Figure 1A). In a 
similar manner, a single injection of 5 mg/kg letrozole (n = 5) produced mechanical 
hypersensitivity after 3 days compared to vehicle treatment (750 mg/kg HPβCD; n = 5), and 
this effect was maintained for at least 30 days (two-way RM-ANOVA with post-hoc t-tests, 
P < 0.05; Figure 1B). Comparing baseline-normalized PWT between letrozole doses did not 
reveal a significant effect of dose, suggesting PWT was maximally reduced by 1 mg/kg 
letrozole. In contrast to letrozole-induced mechanical hypersensitivity, response latency to 
noxious thermal stimulation was not altered at any time points examined after 1 mg/kg or 5 
mg/kg letrozole (two-way RM-ANOVA, P > 0.05; Figures 1C and 1D). Additionally, no 
significant changes in PWL in vehicle treated OVX animals were observed during 30 days 
of evaluation (one-way RM-ANOVA, P > 0.05).
Analysis of all vehicle-treated animals for time and vehicle dose showed PWTs were 
significantly reduced over the course of the experiment (two-way RM-ANOVA, P < 0.05). 
Consequently, we determined whether this reduction was caused by injection of vehicle or 
secondary to OVX by measuring PWT in OVX rats treated with a single injection of 750 
mg/kg HPβCD (n = 5) or saline (n = 5) (Supplemental Figure 1). PWTs were significantly 
reduced over 30 days in all rats independent of vehicle or saline injection, suggesting 
enhanced mechanical sensitivity following ovariectomy is not directly attributable to vehicle 
administration (two-way RM-ANOVA).
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Letrozole produces mechanical hypersensitivity in male rats, without altering thermal 
sensitivity
Male rats were treated with 5mg/kg letrozole (n = 8) or vehicle (750 mg/kg HPβCD; n = 8) 
daily for 15 days and PWT and PWL were measured. When male rats were administered 
letrozole daily, PWT threshold was significantly reduced five days after initiating drug 
administration and at days 10 and 15 during treatment (two-way RM-ANOVA with post-hoc 
t-tests, P < 0.05; Figure 2A). At 5 days of treatment PWT was 5.3 ± 0.5 g in vehicle-treated 
rats and 1.6 ± 0.4 g in letrozole-treated animals. PWT in vehicle-treated male rats did not 
significantly change during the treatment period (one-way RM-ANOVA, P > 0.05; Figure 
2A). After discontinuing drug administration, animals remained hypersensitive to 
mechanical stimulation for at least 72 hours. However, no significant difference in PWT 
between treatment groups was detected 7 days after stopping treatment (experiment day 21), 
suggesting the effect of letrozole was reversible in males (t-test, P > 0.05; Figure 2A). 
Treating male rats with 5 mg/kg letrozole for 15 days did not significantly alter PWLs to 
thermal stimulation when compared to vehicle treated rats (two-way RM-ANOVA, P > 0.05; 
Figure 2B).
PWTs prior drug or vehicle administration were not significantly different between male rats 
(n = 16) and OVX female rats (n = 30) (t-test, P = 0.19). Additionally, PWTs measured at 
day 15 in male rats treated daily with 5 mg/kg letrozole (n = 8) were not significantly 
different than PWTs measured at day 30 in OVX rats treated with 1 mg/kg letrozole (n = 11; 
P = 0.07), 5 mg/kg letrozole (n = 5; P = 0.06), or all letrozole treated OVX rats (n = 16; P = 
0.06).
Letrozole and exemestane augment ATP-induced flinching in male rats
Intradermal injection of purinergic receptor agonists induces overt nociceptive behavior in 
rats as indicated by hind paw lifting and licking activity.(Bland-Ward and Humphrey, 1997). 
Consequently, to examine whether letrozole augments ATP-induced nociceptive behavior, 
male rats were treated with a single dose of vehicle (750 mg/kg HPβCD; n = 7) or with 5 
mg/kg letrozole (n = 6) and 3 hours later flinching behavior in response to intraplantar 
injection of 1000 nmol ATP was observed for 10 minutes. Irrespective of treatment, 
flinching of the injected paw was observed within one minute following ATP injection 
(Figure 3A). The flinching rate (flinches per minute) in 11 of 13 rats was maximal during 
the first two minutes following ATP injection and declined rapidly during the observation 
period. Flinching evoked by intraplantar ATP was significantly greater in letrozole-treated 
rats at 1, 2, and 3 minutes after injection of the nucleotide (Mann-Whitney U test, P < 0.05; 
Figure 3A). Furthermore, letrozole significantly augmented the cumulative number of ATP-
induced flinches over 10 min compared to animals treated systemically with the vehicle 
(Mann-Whitney U test, P < 0.05; Figure 3B).
We also determined whether the effect of letrozole on ATP-induced flinching is maintained 
during chronic administration. For these experiments, male rats were administered AIs or 
vehicle (HPβCD) daily for five days, a time when letrozole-treated rats in our previous 
experiments had significantly lowered PWTs. The day following the last injection, we 
measured flinching in response to 1000 nmol ATP injected in the rat hind paw. In letrozole-
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treated rats (5 mg/kg; n = 10), significantly more flinches were observed 2, 4, 7, 8, and 10 
minutes after ATP injection when compared to vehicle-treated (750 mg/kg HPβCD; n = 13) 
animals (Mann-Whitney U test, P < 0.05; Figure 3C), which was significantly longer than 
the effect after a single dose (figure 3A). The chronic letrozole treatment significantly 
augmented the cumulative ATP-induced flinches observed for 10 min after intraplantar 
injection of the nucleotide (Mann-Whitney U test, P < 0.05; Figure 3D).
In a series of control experiments, male rats administered saline (n = 8) versus vehicle (750 
mg/kg HPβCD; n = 13) daily for five days did not exhibit a significant difference in 
flinching behavior after injection of 1000 nmol ATP (Mann-Whitney U test, P > 0.05; 
Supplemental Figure 2). The median (25th percentile, 75th percentile) of cumulative flinches 
measured for 10 minutes after ATP injection was 17 (9, 24) in saline treated animals versus 
14 (6.5, 22) in vehicle treated animals. In addition, flinching behavior in response to 
intraplantar PBS, the vehicle for intraplantar ATP injections, was measured in male rats 
following administration of saline (n = 5), vehicle (750 mg/kg HPβCD; n = 5), or 5 mg/kg 
letrozole (n = 5) for five days (Supplemental Figure 3). Cumulative flinching behavior 
measured for 10 min after PBS injection was not significantly different between these 
treatment groups (saline: 1 (0, 4.5), vehicle: 1 (0, 3), and 5 mg/kg letrozole: 2 (0, 3)) 
demonstrating that letrozole did not sensitize the rats to the intradermal injection procedure 
(Kruskal-Wallis test, P > 0.05).
We also evaluated whether a mechanism-based inhibitor of aromatase, exemestane (Giudici 
et al., 1988a) could enhance ATP-induced nocifensive behavior. Male rats were administered 
vehicle (1000 mg/kg HPβCD; n = 9) or 30 mg/kg exemestane (n = 7) daily for five days. 
This dose was chosen because it likely produces substantial aromatase inhibition in rats 
(Giudici et al., 1988b; Zaccheo et al., 1989). The day following the last injection, we 
measured nociceptive behavior in response to an intraplantar injection of 1000 nmol ATP. 
The maximal flinching rate of all rats occurred within the first minute of observation and 
diminished during the 10-minute observation period. Flinching behavior in exemestane-
treated rats was greater than in those receiving vehicle at 8, 9 and 10 minutes following ATP 
injection (Mann-Whitney U test, P < 0.05; Figure 3E). Cumulative flinching over the 10 min 
after intraplantar injection of 1000 nmol ATP was significantly greater in exemestane-treated 
rats when compared to vehicle treated animals (Mann-Whitney U test, P < 0.05; Figure 3F).
Systemic letrozole treatment potentiates the excitability of small-diameter and medium-
diameter sensory neurons
Because an increase in excitability of sensory neurons could contribute to the AI-induced 
increase in mechanical sensitivity, we examined whether repeated systemic administration of 
letrozole would augment excitability of small and medium sized sensory neurons. Using 
neurons isolated from DRGs of male rats treated for 5 days with 5 mg/kg letrozole or 
vehicle, we determined the number of APs elicited in response to a 500 pA ramp of 
depolarizing current delivered over 1 second. Representative responses of small and medium 
diameter neurons from each treatment group are shown in Figure 4 and cumulative results 
from 6 letrozole-treated and 6 vehicle-treated rats are summarized in Table 1. A 
representative small diameter neuron from a vehicle-treated rat elicited 5 APs in response to 
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the ramp of depolarizing current (Figure 4A), whereas a representative small-diameter 
neuron from a letrozole-treated rat fired 21 APs in response to the same stimulus (Figure 
4C). In small diameter neurons, the 500 pA ramp elicited significantly more APs in neurons 
from letrozole-treated rats (22.8 ± 1.2, n = 6) than those from vehicle-treated rats (4.3 ± 0.6, 
n = 6) (t-test, P < 0.05; Table 1). In a representative medium diameter neuron harvested from 
a vehicle-treated rat, the ramp of current generated 3 APs (Figure 4B), whereas the same 
ramp elicited 16 APs in a representative medium diameter neuron from a letrozole-treated 
rat (Figure 4D). In this neuronal population, the 500 pA ramp elicited significantly more 
APs in neurons from letrozole-treated rats (14.3 ± 1.7, n = 6) than those from vehicle-treated 
rats (3.2 ± 1.1, n = 6) (t-test, P < 0.05; Table 1). No medium diameter neurons examined in 
these experiments were sensitive to capsaicin, whereas all the small diameter neurons 
displayed capsaicin sensitivity.
We next determined whether the minimum current required to elicit a single AP (rheobase) 
was altered in sensory neurons following systemic letrozole exposure. Representative traces 
resulting from the rheobase protocol are shown in Figure 5. In sensory neurons isolated from 
the DRGs of rats treated with vehicle for 5 days, the average rheobase measured in small and 
diameter neurons was 413.3 ± 67.3 pA and 286.7 ± 39.6, respectively (Table 1). When 
compared to controls, the rheobase measured in sensory neurons from animals treated for 5 
days with 5 mg/kg letrozole were significantly lower (40.0 ± 5.2 pA and 86.7 ± 24.0 in small 
and medium diameter neurons, Table 1), consistent with the ability of letrozole to enhance 
the number of evoked APs.
As summarized in Table 1, several additional electrophysiological parameters were altered in 
sensory neurons from letrozole-treated animals, indicating that systemic exposure to this 
drug enhances basal excitability. Resting membrane potentials of small and medium 
diameter neurons were significantly depolarized in letrozole-treated rats compared to 
controls (t-test, P < 0.05; Table 1). Additionally, the latency to fire APs following current 
injection was significantly shorter in all sensory neurons from the letrozole group (t-test, P < 
0.05; Table 1). Letrozole exposure also significantly reduced firing thresholds (membrane 
potentials at which APs initiate) (t-test, P < 0.05); however, this effect was only significant 
in small diameter neurons (Table 1). Finally, we observed a marked increase in input 
resistance in small diameter neurons from letrozole treated animals compared to vehicle 
controls (t-test, P < 0.05), but no change in input resistance was seen in medium diameter 
neurons (Table 1).
Neuropeptide release from spinal cord slices is not altered in male rats treated with 
letrozole
To determine whether letrozole altered release of iCGRP into the spinal cord from sensory 
neuron central terminals, male rats were treated with 5 mg/kg letrozole (n = 6) or vehicle 
(750 mg/kg HPβCD; n = 7) daily for 7 to 8 days. PWT was measured at baseline and 
following 1, 3, and 6 days of treatment in all animals that were used in release experiments. 
Consistent with our previous results, 5 mg/kg letrozole significantly reduced the PWT 
compared to vehicle treated controls from 7.0 ± 1.0 grams to 2.7 ± 0.9 grams and 1.6 ± 0.2 
at days 3 and 6 following initiation of treatment (two-way RM-ANOVA with post-hoc t-
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tests, P < 0.05). The day after the last drug dose, we measured iCGRP release from spinal 
cord slices under basal conditions and during depolarization with 30 or 50 mM KCl. Basal 
iCGRP release from spinal cord slices isolated from letrozole-treated rats (0.040 ± 0.004 % 
of total content per min) was not significantly different from vehicle-treated rats (0.040 
± 0.003 % of total content per min) (t-test, P > 0.05; Figures 6A–C). Furthermore, iCGRP 
release during exposure to 30 mM KCl was not altered in spinal cord slices from rats treated 
with letrozole compared to vehicle (vehicle: 0.049 ± 0.005 versus letrozole: 0.048 ± 0.005 % 
of total content per min (t-test, P > 0.05; Figures 6A–C). Consequently, evoked iCGRP 
release from letrozole treated rats (0.008 ± 0.002 % of total content per min) was not 
different from that of vehicle treated rats (0.009 ± 0.003 % of total content per min) (t-test, P 
> 0.05; Figure 6C). Similarly, systemic exposure to 5 mg/kg letrozole for 7 days did not 
augment iCGRP release from spinal cord slices stimulated with extracellular potassium 
concentrations sufficient to elicit significant peptide release from basal conditions (t-test, P > 
0.05; Figure 6D–F). iCGRP content in the lumbar spinal cord was not different in male rats 
administered 5 mg/kg letrozole (423.6 ± 35.0 fmol/mg, n = 11) versus vehicle (482.6 ± 40.8 
fmol/mg, n = 13) (t-test, P > 0.05).
Discussion
Postmenopausal breast cancer patients undergoing treatment with AIs frequently develop 
musculoskeletal pain that reduces their quality of life and may lead to treatment 
discontinuation. Using male and OVX rat models that mimic the low circulating estrogen 
concentrations observed following menopause, we have shown that systemic administration 
of AIs induces hypersensitivity to cutaneous mechanical stimuli and augments the 
nociceptive response to the algogen ATP. Our experiments in OVX rats were conducted two 
weeks following ovariectomy, when serum estrogen concentrations are significantly depleted 
(Pfaff, 2002). Of note, serum estradiol concentrations in OVX and male rats have been 
reported to be between 1 and 3 pg/mL when measured by radioimmunoassay (Kuba et al., 
2006; Strom et al., 2008a; Strom et al., 2008b), however the true concentrations may be 
much lower given the lack sensitivity and specificity of steroid radioimmunoassays in this 
concentration range (Santen et al., 2007).
We observed that male rats treated with letrozole daily for 15 days showed a significant 
reduction in the paw withdrawal threshold to mechanical stimuli without any change in 
withdrawal latency to thermal stimuli. When injections were stopped, mechanical 
hypersensitivity in letrozole-treated males was reversed by seven days. We also observed 
mechanical hypersensitivity in OVX rats after a singe dose of 1 or 5 mg/kg letrozole and this 
effect was maintained for the 30 days of behavioral testing. The drug effect was maintained 
despite a progressive reduction in PWTs of control OVX rats throughout the testing period, a 
finding that is consistent with previous studies demonstrating that ovariectomy enhances 
mechanical sensitivity in animals (Dina et al., 2001; Ma et al., 2011; Sanoja and Cervero, 
2005). Our current findings expand on previous work showing AIs alter nociceptive 
responses in male C57BL6 mice (Fusi et al., 2014). Interestingly, in comparison to a 
persistent reduction in PWTs observed in letrozole-treated rats, mechanical hypersensitivity 
reported in mice was transient and reversible during daily chronic AI administration (Fusi et 
al., 2014). Therefore, differences in the expression and time-course of AI-induced 
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hypersensitivity may be varied depending on species-specific mechanisms mediating AI 
effects.
Our observed differences in the time course of nociceptive behavior between males and 
OVX females given the treatment regimens could be secondary to sex differences mediating 
nociception and analgesia, as have been suggested by many clinical and pre-clinical pain 
studies (Craft et al., 2004). For example, differences between males and females have been 
observed in the nociceptive response to capsaicin (Lu et al., 2009), in animal models of 
chemotherapy-induced peripheral neuropathy (Joseph and Levine, 2003), and in nociceptive 
changes due to inflammation (Mannino et al., 2007). These differences are often attributed 
to multiple factors, including the organizational and activational consequences of 
reproductive hormone differences between sexes. Consequently, treatments that alter 
endogenous sex steroids may differentially alter nociception in males and females. For 
example, inhibiting aromatase eliminates one metabolic pathway of androgen metabolism, 
and therefore AI treatment could alter concentrations of other tissue steroids that might 
contribute to hypersensitivity. Indeed, AIs are known to increase blood concentrations of the 
aromatase substrate testosterone in males (Burnett-Bowie et al., 2009; Mauras et al., 2000), 
but have little effect on testosterone levels in females (Gallicchio et al., 2011; Ingle et al., 
2010; Rossi et al., 2009). Alternatively, sex differences seen in the current work could be due 
to pharmacokinetic differences. Long-term behavioral changes in female rats are consistent 
with slower elimination of letrozole in this sex, which can produce prolonged tissue 
exposure and long-term suppression of estrogen synthesis following a single dose of the AI 
(Wempe et al., 2007). Therefore, in addition to the potential species-specific effects of AIs 
on hypernociception, our results suggest there also may be sex-dependent effects.
In our experiments, male rats and OVX female rats did not exhibit a thermal hyperalgesia 
after letrozole treatment. Hypersensitivity to noxious heat applied to the hind paw is often 
detected in models associated with involvement of inflammatory mediators, such as 
carrageenan-induced arthritis, collagen-induced arthritis, or nerve growth factor, which lead 
to functional changes in thermosensitive sensory fibers (Inglis et al., 2007; Malfait et al., 
2013; Mills et al., 2013; Zhang et al., 2001). Conversely, heat hypersensitivity is not 
characteristic of chemotherapy-induced peripheral neuropathy, as modeled in animals (Xiao 
et al., 2012) or with AI-induced arthralgia. Mechansitically, AI-mediated hypersensitivity 
may therefore share underlying changes associated with other drug-induced pain syndromes 
with a significant mechanical, but not thermal component, or there may be commonalities in 
altered function of the underlying sensory fibers.
Both letrozole and exemestane, which are structurally distinct AIs that inhibit aromatase 
through different mechanisms, significantly increased flinching behavior induced by 
intradermal injection of ATP. We chose to examine the effects of ATP since activation of 
P2Y and P2X nucleotide receptors contributes to inflammatory and neuropathic pain 
behaviors in rodents (Chen et al., 2005; Cockayne et al., 2000; McGaraughty et al., 2003; 
Souslova et al., 2000; Tsuda et al., 1999). Previous studies also have shown that systemic 
estradiol treatment partially attenuates overt nociception in rats induced by ATP (Ma et al., 
2011). Estradiol similarly attenuates overt nociception induced by the P2X-selective agonist, 
α,β-me-ATP, when the compounds are coadministered in the paw (Lu et al., 2013), 
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suggesting that estradiol can modulate ATP-evoked behavior when sufficient local 
concentrations of the steroid are achieved. We observed that intradermal injection of 1000 
nmol ATP rapidly initiated a flinching response of the injected paw that subsided over 
approximately 10 minutes in control animals, consistent with previous studies of behavior 
evoked by ATP and ATP analogs (Bland-Ward and Humphrey, 1997; Hamilton et al., 1999). 
Treating male rats systemically with letrozole and exemestane for five days augmented overt 
nociceptive responses to intraplantar injection of ATP. These data suggest that AIs enhance 
the algogenic effects of ATP through a mechanism potentially mediated by estrogen. Our 
findings are consistent with prior studies showing letrozole treatment in rats and genetic 
ablation of aromatase in knockout mice enhances formalin-induced nocifensive behavior 
(Moradi-Azani et al., 2011; Multon et al., 2005). Since overt nociception induced by 
formalin is attenuated by P2X receptor antagonists and by genetically ablating P2X3 
receptors in mice (P2X3−/−), enhanced purinergic receptor sensitivity may underlie the 
ability of letrozole to potentiate hypernociceptive responses to ATP and to formalin 
(Cockayne et al., 2000; McGaraughty et al., 2003; Souslova et al., 2000).
AIs are specifically indicated for treating breast cancer in postmenopausal women. Our 
studies used OVX female and male rats since they have low circulating estrogen 
concentrations that mimic the blood concentrations observed in women following 
menopause. Consequently, under these conditions it is more likely that AIs enhance 
nociception through a mechanism that depletes tissue estrogens rather than circulating levels 
of the hormone. Although blood estrogen concentrations in ovariectomized rodents are 
reduced to concentrations observed in males (Davidge et al., 2001; Farrell et al., 1988; Zhao 
et al., 2004), aromatase expression and activity in extra-gonadal tissues persists following 
OVX (Zhao et al., 2004). Of note, the capacity for de novo synthesis of estrogens and other 
steroids in the vertebrate nervous system is well established. In the central nervous system, 
aromatase is expressed in neuronal cell bodies, presynaptic boutons and postsynaptic 
neurons and in glia (Hojo et al., 2004; Naftolin et al., 1996; Peterson et al., 2005; Schlinger 
et al., 1994). Aromatase has also been shown in the dorsal spinal cord of the Japanese quail 
(Evrard et al., 2000) and aromatase immunoreactivity and synthesis of 3H-estradiol from the 
steroid precursor 3H-pregnenolone was shown in lumbosacral DRGs from rats (Schaeffer et 
al., 2010). Aromatase expression in DRG neurons coincides with expression of classical 
nuclear estrogen receptors, ERα and ERβ, and of GPR30, which are additionally expressed 
in spinal dorsal horn neurons (Papka and Storey-Workley, 2002; Takanami et al., 2010; 
Taleghany et al., 1999; Vanderhorst et al., 2005).
We observed an increase in the number of APs fired in response to depolarizing current in 
sensory neurons isolated from rats treated with 5 mg/kg letrozole for 5 days. In response to a 
500 pA ramp of current, letrozole treatment resulted in a 5.3-fold and a 4.5-fold increase in 
APs fired by small and medium diameter neurons respectively, and these changes were 
associated with a reduction in the amount of current needed to evoke an AP. Although our 
experimental design precludes determining whether these neurons are nociceptors, both 
small diameter and medium diameter sensory neurons respond to mechanical stimulation 
(Leem et al., 1993). Thus, it is interesting to speculate that the enhanced excitability could 
be a mechanism that accounts for the pro-nociceptive effects of letrozole. Our 
electrophysiological observations were made 2 to 6 hours after harvesting neurons; during 
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which time the isolated neurons were not re-exposed to letrozole. Previous 
electrophysiological studies have shown systemic estrogen administration to OVX rats 
augments the excitability of trigeminal neurons, when measured 3 to 8 hours after isolation 
(Flake et al., 2005). These findings suggest that either increasing or decreasing the local or 
systemic concentrations of estrogens produces long-lasting and persistent changes in the 
excitability of sensory neurons. These observations are consistent with the persistence of 
letrozole-induced mechanical hypersensitivity in rats.
The letrozole-induced changes in parameters of excitability strongly suggests that systemic 
treatment with this AI can enhance activity of sodium channels responsible for initiation of 
APs (Gurkiewicz et al., 2011). Furthermore, the significant increase in repetitive firing of 
APs suggests that letrozole exposure downregulates activity of voltage-activated potassium 
channels that mediate repolarization of the membrane potential (Nicol et al., 1997). 
Similarly, the increase in input resistance from sensory neurons isolated from letrozole-
treated animals indicates a reduction in conductance across leak potassium channels that set 
the resting membrane potential in sensory neurons (Meuth et al., 2009). Consistent with 
these findings, there was also a significant depolarization of the resting membrane potential. 
The fact that letrozole alters excitability of sensory neurons suggests that modifying ion 
channel activity could prove to be an important therapeutic strategy for treating AI-induced 
arthralgia in patients. In support of this notion, recent work also suggests that AI-induced 
pain behaviors in mice are mediated by the TRPA1 (Fusi et al., 2014). Although the 
mechanism underlying the ability of letrozole to enhance excitability of sensory neurons is 
unknown, the effects may be mediated by changes in tissue estrogens. There is precedent for 
this idea since estrogens have been shown to directly interact with ion channels in neurons 
(McRoberts et al., 2007; Xu et al., 2008). Furthermore, estrogens can alter ion channel 
expression at the cell surface (Bosch et al., 2013), and indirectly alter ion channel activity by 
changing the expression and/or activity of ion channel modulators (Diogenes et al., 2006; 
Kelly and Ronnekleiv, 2009).
Interestingly, we observed that systemic treatment with letrozole enhances excitability of 
both medium diameter capsaicin insensitive and small diameter capsaicin sensitive sensory 
neurons. Either activation or inhibition of TRPV1, the pharmacologic target of capsaicin in 
sensory neurons, does not alter mechanical hypersensitivity in naïve rats; however, TRPV1 
sensitization following spinal cord injury and inflammation does enhance sensitivity to 
mechanical stimuli (Brenneis et al., 2013; Wu et al., 2013). In rat sensory neurons, many 
TRPV1-expressing neurons co-express the neuropeptide CGRP (Price and Flores, 2007). 
CGRP is synthesized and released from a number of nociceptive sensory neurons including 
mechanosensitive C-fibers (Dubin and Patapoutian, 2010; Lawson et al., 2002; Lawson et 
al., 1997). When released by nociceptors in the periphery, CGRP produces neurogenic 
inflammation that in turn sensitizes nociceptors in the periphery (Brain and Williams, 1985; 
Richardson and Vasko, 2002). ERα is known to be co-expressed with CGRP in sensory 
neurons and estradiol increases CGRP mRNA and CGRP content in a concentration and 
time-dependent manner (Gangula et al., 2000; Mowa et al., 2003). Additionally, recent 
studies show CGRP release is stimulated by ex vivo treatment of mouse spinal cord slices 
with AIs (Fusi et al., 2014). Consequently, we chose to examine whether chronic 
administration of letrozole to rats would alter the content or release of CGRP from sensory 
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neurons in spinal cord slices taken from these animals. Our results show that basal iCGRP 
release from spinal cord tissue of letrozole-treated rats was not different than vehicle-treated 
controls, suggesting that letrozole treatment does not result in persistent activation of CGRP 
expressing nociceptors. Underlying differences between these findings and those reported in 
the mouse by Fusi and co-workers are unclear. However, the letrozole concentrations used 
by Fusi et al. were approximately 500-fold higher than the maximum plasma concentrations 
achieved by doses that elicited hypersensitivity responses in mice. In addition, our results are 
consistent with our electrophysiological studies showing a lack of spontaneous AP firing in 
sensory neurons from letrozole-treated rats (data not shown). Furthermore, we observed no 
change in the potassium-stimulated release of CGRP in sensory neurons from letrozole-
treated rats. While previous studies have provided evidence for the regulation of CGRP 
expression by exogenous estrogens, we observed no change in total content of iCGRP in 
vivo after systemic letrozole for up to five days. Taken together, our results do not support 
altered release of this neuropeptide into the spinal cord as a molecular mediator of letrozole-
induced hypersensitivity, but do not preclude a potential effect on other neurotransmitters or 
other sensory neuron populations. Indeed, a number of mechanosensitive Aδ- and C-fibers 
do not express CGRP (Dubin and Patapoutian, 2010; Lawson et al., 2002) and thus, the 
effects we observed on nociception could be mediated by these neurons. Our studies are the 
first to demonstrate that AI exposure significantly alters the excitability of sensory neurons, 
although the molecular mechanisms of AI-enhanced excitability and its contribution to AI-
induced hypersensitivity remain to be elucidated. Thus, further studies are warranted to 
identify the mechanism underlying these effects and to determine which subpopulations of 
neurons are affected by treatment with letrozole or other AIs.
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PWT paw withdrawal threshold
PWL paw withdrawal latency
DRG dorsal root ganglia
OVX ovariectomized
AP action potential
CGRP calcitonin gene-related peptide
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Highlights
• Systemic aromatase inhibitor administration alters nociception in male and OVX 
rats
• AI treatment results in mechanical and chemical, but not thermal 
hypersensitivity
• Peripheral sensory neurons display enhanced excitability following AI treatment
• AI treatment does not alter CGRP release from sensory nerve terminals in the 
spinal cord
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Figure 1. A single dose of letrozole induces sustained mechanical, but not thermal 
hypernociception in ovariectomized rats
Each point represents the mean ± S.E.M. of (A, B) paw withdrawal threshold (PWT) in 
grams or (C, D) paw withdrawal latency (PWL) in seconds. Letrozole (1 mg/kg: A, C or 5 
mg/kg: B, D) or vehicle was administered in a single dose on day 0 (as indicated by the 
arrows). An asterisk represents significant differences in PWT following treatment with 1 
mg/kg letrozole versus vehicle, whereas a cross represents significant differences in PWT 
following treatment with 5mg/kg letrozole versus vehicle using two-way RM-ANOVA 
followed by post hoc two-sample t-tests.
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Figure 2. Daily dosing of 5 mg/kg letrozole induces mechanical, but not thermal 
hypernociception in male rats
Each point represents the mean ± S.E.M. of (A) paw withdrawal threshold (PWT) in grams 
or (B) paw withdrawal latency (PWL) in seconds. Letrozole or vehicle was administered 
daily on days 0 through 14 (15 total doses) as indicated by the horizontal line during which 
behavior was measured (solid lines). PWT continued to be measured following drug 
discontinuation (dashed lines in (A)). An asterisk represents significant differences in PWT 
between treatment groups using two-way RM-ANOVA followed by post hoc two-sample t-
tests.
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Figure 3. Letrozole and exemestane augment ATP-induced nocifensive behavior in male rats
A, C and E: Each point represents the mean ± S.E.M. of flinches observed in one minute 
intervals after injection of 1000 nmol ATP. In (A), rats were treated acutely with 5 mg/kg 
letrozole or vehicle as indicated and injected with ATP 3 hours later, whereas in (C) and (E), 
animals received 5 mg/kg letrozole, 30 mg/kg exemestane, or vehicle daily for 5 days and 
then were injected with ATP one day after the last injection. An asterisk represents 
significant differences in the number of flinches observed in one-minute intervals between 
treatment groups using the Mann-Whitney U test. B, D and F: Cumulative hind paw 
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flinches observed for ten minutes following ATP injections are presented as box plots for 
each treatment group. The pound symbol indicates significantly different ATP-induced 
cumulative flinches in rats treated with vehicle versus letrozole or exemestane using the 
Mann-Whitney U test.
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Figure 4. Systemic administration of letrozole enhances the number of evoked APs in small- and 
medium-diameter sensory neurons
Representative action potentials in response to a 500 pA ramp of depolarizing current over a 
1000 ms stimulus. A and B: The top panel shows representative APs from small- (A) and 
medium-diameter (B) sensory neurons isolated from animals treated with vehicle daily for 5 
days. C and D: The bottom panel shows representative APs from small- (C) and medium-
diameter (D) sensory neurons isolated from animals administered 5 mg/kg letrozole daily for 
5 days.
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Figure 5. Systemic administration of letrozole attenuates the rheobase in small- and medium-
diameter sensory neurons
Representative traces and current-clamp protocols used to the determine rheobase. A and B: 
Small- (A) and medium-diameter (B) sensory neurons isolated from rats administered 
vehicle for 5 days. Current was injected for 200 ms in increments of 80 pA until the firing of 
a single AP was elicited. C and D: Neurons isolated from rats treated with 5 mg/kg letrozole 
for 5 days. Small- (C) and medium-diameter (D) neurons were injected with current in 
increments of 20 pA until the firing of a single AP was elicited.
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Figure 6. Release of iCGRP is not altered in spinal cord slices from male rats with letrozole-
induced mechanical hypersensitivity
A, B, D and E: Basal and potassium-stimulated release of iCGRP was measured from spinal 
cord slices isolated from rats following treatment with vehicle (A, D) or 5 mg/kg letrozole 
(B, E) for 7–8 days. Open columns represent iCGRP released from spinal cord slices 
perfused with HEPES buffer alone for successive 3-minute intervals, whereas black columns 
represent iCGRP released when tissues were perfused with HEPES buffer containing 30 mM 
(A, B) or 50mM potassium (D, E). The ordinate represents the mean ± S.E.M. of iCGRP 
released per minute, expressed as the percent of total iCGRP content in the spinal cord slice. 
C and F: Summary of mean ± S.E.M. of iCGRP release as percent of total content/min 
during basal (minutes 9–18) and high potassium stimulation (minutes 18–27) in vehicle or 
letrozole-treated rats from (A - E). Evoked release is calculated as stimulated release minus 
basal release. Asterisks indicate significant differences in iCGRP release between stimulated 
and basal conditions using two-sample t-tests.
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Table 1
Effects of systemic letrozole exposure on excitability parameters of sensory neurons a
Small diameter neurons Medium diameter neurons
Vehicle Letrozole Vehicle Letrozole
Resting Membrane Potential (mV) − 65.0 ± 1.5
− 47.3 ± 0.6 * − 61.8 ± 1.2 − 49.4 ± 2.5 *
Number of Action Potentials 4.3 ± 0.6 22.8 ± 1.2 * 3.2 ± 1.1 14.3 ± 1.7 *
Firing Threshold (mV) − 7.4 ± 3.8
− 18.9 ± 1.6 * − 12.3 ± 3.3 − 15.1 ± 3.2
Latency to Fire (ms) 830.5 ± 20.3 220.0 ± 21.3 * 843.9 ± 65.3 329.5 ± 52.3 *
Rheobase (pA) 413.3 ± 67.3 40.0 ± 5.2 * 286.7 ± 39.6 86.7 ± 24.0 *
Input Resistance (MΩ) 506.8 ± 99.2 1068.3 ± 184.8 * 656.7 ± 120.6 932.5 ± 268.8
a
Data are presented as mean ± S.E.M. for small diameter (~20 µm, N=6) and medium diameter (~35 µm, N=6) sensory neurons.
An asterisk indicates a significant difference between treatment groups (two-tailed t-test, p < 0.05).
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